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Association of  Pre-lntervent!on Aotivatcd Clotting 
. . . .  ]_trees (AGg") and Clinical Outcomes Following 
Percutaneous Coronary Revasculaflzation: Results 
From the IMPACT-II Trial 
Frank V. Agulrre, James J. Ferguson, James C. Blankanship, Karen 
S. Pleper, Marc Taylor, Robert A. Harrington, MIchele Rund, Eugene 
A, Caracololo, Thomas J. Dnnot, ue, Robert M. Caliri, A. Michael Uncoff, 
James E, Tcheng, Eric J. Topoi. for the IMPACT-II Investigators. St. Louis 
Univet~ity, St. Louis, MO 
Pdor studies show high rates of adverse clinical outcomes with low prosedural 
ACTs during coronary revascularization, We evaluated ACTs and clinical 
OUtcomes of 3296/4010 (8P/o) pts enrolled tn the IMPACT.II •al In whom 
pro-intervention ACTS were available. All pts received aspirin and weight- 
edjusted IV hepadn to achieve a pre-interventlan ACT of 300-350 secs. Pie 
were randomized to receive placebo (n : 1t04) or integrelin (n ,= 2192). 
Pdmaw endpoint was the 30.day combined (ncldanca of death, M1, or urgent 
revasculadzation. Pra-lnten~ntion median ACTs were 33I vs 324 sees in pta 
with and without a primery endpoint. PdmaW ~pclnts w6re more frequent 
Pro-intervention Primary Endpotnt, . 
ACT Terlile (~)  Placebo Imegrelin 
< 30~ 9% 9% 
303-.352 12% lO% 
> 353 15% 10% 
Conclusion: IMPACT-U pre-interventional ACT data demonstrate similar 
rates of adverse outcomes in integralin-treated pts regardless of ACT, but 
appeared to p~radoxically occur mere frequently, over a narrow but increas- 
Ing ACT range in ~.%¢bo pLY. ~'~,,i: often ~,?.ppears to be attenuated by GP 
Ilb/ll;a antagonism. Those unexpected results raise the question as to mech- 
anism and accuracy of recommended ACT thresholds based on empiric 
studies. 
Pharmscoiogl¢ Modulation of the Collateral 
Vascular Resistance in AcUte and Chronio Coronary 
O~lus ion  Assessed by  Intraooronary Blood Row 
Velocity Analysis 
Jan J. Piek, Rob A.M. van Lisbergen, Karet Th. Koch, Ran J.G. Peters, 
George K. David. Academic Medical Center, Amsterdam, the Netherlands 
Aim of the study: To assess the direct erie= of vasodiisfurs on coronary 
collateral vascular esistance in acute and chronic coronary occlusion. 
Methods: Patients with 1-vessel disease, antegrade flow and presence of 
collateral vessels during balloon coronary occlusion (BCO, n = 25, group I) 
were compared with patients with a collateralized 1-vessel chronic coronary 
occlusion (n = 18, group II). Presence of collateral vessels during BCO was 
determined by anglography of the donor artery (grade 2--3 according to 
Rentrop's dassitication). Collateral flow (Vcall) was assessed in the recipient 
coronary artery during BCO by the distal maximal diastolic blood fl0w velocity 
(> 5 cm/esc) with the use of a 0.014" Doppler tipped guidewtre. Adenosine 
(12-18/~g) and nitroglycerin (0.1-0.2 mr) were injected separately as a 
bolus in the donor coronary artery during subsequent BCO's to assess the 
effect on Vccll. Aortic pressure (Pea) end coronary wedge pressure (Pw) 
were used to calCulate the relative collateral vascular esistance: Rccll = Pea 
- PwNcclt (mmHg/cm/sec). 
Results: Collateral flow was detected In 14 of the 25 patients (56%) in 
group I and in all patients in group II. 
Baseltne Adenosine Nitroglycerin 
Group Ir ~ VC0il 15.8 4- 9IS 17.14"10 17.~ 4' 11 
(n'* 14) PW/Pao 0.384-0.13 0.384-0.1 0,41 4-0.15 
Rcotl 5,4 4- 3.9 5,3 4. 4.2 5.4 4- 5.3 
Group, Vcoll 18.44-7.7 24.3± 10t 24.94-10 t 
(n,~ 18) Pw/Pao 0.464-0.12 0.424-0.08 0.46~ 0.12 
RcOll 3.4 4- 1.6 2.7 4-1.4" 2.5 4-1.3 t
*p < 0,05; tp < 0 005. compared to baseline values by paired t-test, 
Conclusion: The collateral vascular resistance In chronic coronary ocolu, 
slon ?,,an be reduced, in contrast o the setting of acute coronary occlusion, 
by vesodilators of the arterioler esistance vessels as well as by vasndiistors 
that exert heir effect on the conductance arteries. 
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/de ntiflc~t, ion of.Ultra Low-Risk Patients Following 
~ lmary  Angloplasty for Acute Myocardial Infarction 
Theodore Schreiber, Dominic Marsatese, John Griffin, Bryan Donohue, 
A. Sampoclesi, Constantine Constantinl, Gregg Stone, Denise E. Jones, 
Dabrs Sachs, Denise Mason, Thomas W~arton, Donald Rothbaum, 
Bruce Brodie, William W. O'Neill, Cindy L. Grines. Wil/iarn Beaumont 
Hospital, Royal Oak, MI 
Hesfth care reform mandates cost containment, therefore hospitals are being 
scrutinized to discharge patients early. In the PAMI-2 study, the performance 
of acute catherization and primary PTCA has been shown to achieve high 
rates of reporfuslon and permit the triage of tow-risk patients (age < 70, 
LVEF > 45%, 1-.2 vessel CAD) to be admitted to a telemetry unit and early 
discharge at 3 days. To determine whether this paradigm further permits e- 
ts=ion of an "ultra low" risk (ULR) subgroup otentially eligible for discharge 
at 48 hours, a cohort of tow-risk PAMI-2 patients with TIMI-3 tiow, residual 
stenosts < 30%, age < 60, single vessel disease with no thrombus/dissection 
after pdrrary PTCA were evaJuated, 
E~lpoint ULR (N = 150) .... Low Risk (N - 3o9) p 
Death 0.0% 0.65% 0.32 
Rslnfarction 0.67% 3,88% 0.05 
Reocolusion 0,67% 4.21% 0.03 
CVA/TIA 0 1,09% 0.11 
CHF 0,67% 3.88% 0.05 
Combined 1.S3% 8,74% 0.002 
The combination of clinical and cath descriptors and excellent angiogrsphi¢; 
results following primary PTCA permits identification of a subgroup of AMI 
patients with an extremely benign course, potentially eligible for dissharge at 
48 hours. This finding has important cost implications. 
• Post-Intervention Cardiac Enzyme Elevations: 
Prognostic Slgrdflcance in IMPACT Ii 
Barbara E. Tardiri, Robert M. Calift, James E. Tcheng, A. Michael Lincoff, 
KfistJna N. Sign~n, Robert A. Herrington, Kenneth W. Mahatley, 
Paul Teirstein, James Heinsimer, Eric J. Topoi, for the IMPACT-11 
Investigators. Duke University, Durham. NC 
The significance of CKMB elevations after coronary intervention was exam- 
ined in the IMPACT II tflal evaluating intsgrslin in PTCA. This analysis in- 
cluded the 2432 patients with available CKMB levels in the post-intervention 
period (4-20 hr). 1795 patients (74%) had no elevation; 328 (14%) hnd 
CKMB 1-3 times the institutional upper limit of normal; increases were 3- 
5x In 83 (4%), 5--10x in 92 (4%) and > 10x in 123 (5%) patients. Clinical 
outcomes, including subsequent myocardial infarctions (MI), were stratified 
by post.procedure CKMB (multiple of normal). CABG and PTCA include 
urgentJeme,gancy procedures only, Patients with elevated CKMB after suc- 
cessful revascularizations (composite of death, MI, procedures-It.5%) had 
fewer events than patients with unsuccessful interventions (29.8%) but more 
than patients with normal post-procedural CKMB (3.0%). 
30-i mB]O-] IBI-3 m3,$ m5-10 D>t0 
20, 
0.  ! __m-I : 1 - 1 l 
Composite Death MI CABG PTCA 
Conclusion: Elevations in CKMB fullowir,~, even successful psrcutanecus 
interventions may identify a pepulatio,9 at high risk for future events. The 
degree of dsk is proportional to the dee in CKMB. 
Predlctom of Abrupt Closure and Consequences of 
Emergency Endpolnts In the IMPACT II Trial 
Brace A. Bergelson, Charles J. Davidson, Gail Harley, Russell Ivanhoe, 
James J. Ferguson, Barbara E. Tardiff, Kenneth W. Mahariey, A. 
Michael Uncoff, James T. Tcheng, Robert M. Caliri, Edc J. ToFol, for the 
IMPACT II Investigators. Northwestern Univ., Ch~,  IL 
To evaluate the predictors of abrupt vessel closure (AC) in patients treated 
with the GP Ilb/Ita antagonist, Integ~in, asubgroup analysis was performed 
within the IMPACT II trial. Compared with placebo (n = 1328), Integrelin (n = 
2682) reduced the incidence of AC from 5.0% to 3.1% {p = 0.004) and need 
fur emergent CABG from 2.8"/o to 1.8% (p = 0.034). Signif'P.ant multivariate 
predictors of AC after adjusting for treatment were: 
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Vadabte p-Value Odds Ratio 
Post % Stenosis 0.001 1.25 per 10% f 
DCA 0*0006 3.29 
Thrombus 0.0001 10.19 
Major Dissection 0.0001 16.59 
Di~d~el~ Mellitus 0.018 0.72 
Mulltvessel Dtsease 0.029 1.47 
There was no differential effect of Integrelin on the risk factors for AC. 
Consequences of AC including in.hospital and 30 day death, MI, and CABG, 
were unaffected by treatment. In patients requiring emergent CABG, there 
was no excess in bleeding complications: 
Inlegmlin (n = 49) Racebo (n - 37) p-value 
Major ~ to~ 10.5% 24.3% 0.08 
RBC transfusion 63.3'Y,, 75.7% 0.22 
P1stelet transfusion 51.0% 37.8% 0,22 
In conclusion, 1) integrelin significantly reduced the dsk of abrupt closure, 
without a differential effect on dsk factore or sequelae. 2) The bleeding dsk in 
patients requiring emergent CABG was not increased in the Integrefin group. 
~"~ Comparison Between Unfractionated and Hepadn 
Low Molecular Wetght Hepadn During 
Percutaneous Transiuminsl Coronary Angioplasty 
in the 24 Hours After Intervention 
Rooul Bonan, Melitta B. Preisack, Karl R. Karsch, the REDUCE Study 
Group. Montreal Heart Institute, Montreal, Quebec, Canada 
The efle~-I of two different kinds of hepadn, an unfraction~ted (H) and a low 
molecular weight (LMWH), revipadn, was examined in coronary angioplasty 
(PTCA), regarding the level st anticoagulation and immediate results. Six 
hundred and twelve patients were randomized between H and LMWH in the 
setting of the REDUCE trial, Partial thremboplastin time (PTT) was measured 
twice a day following 24,000 U of H over 24 hre of intravenous infusion/twice 
daily placebo s.c. injections in group I (306 pts) and after 10,500 U infusion 
of revipadn followed by twice a day 3,500 U s.c. application of revtpadn in 
group It (308 pts). 
Group t Group II P 
Fr'r (mean sac) 84.4 48,S 0.017 
Myocardial infarction 6 9 0*782 
Death 0 0 - 
Stem implantation 2t 6 0.003 
Autoperfttsion t~ffoone 16 9 0,096 
Herr~t0rr~ 26 12 0*065 
Decrease tn hemoglobin >2 g/dl 62 35 0.002 
Major bleedings 8 7 0*800 
Conclusions: A standard ose of revipadn applied in coronary angioplasty 
is associated with batter immediate results and tess hemorrhagic 0mpfi- 
cations than hepadn. Moreover, this uniform dose of LMWH eliminated the 
need for follow.u,'~ PTi'. 
Ef fects of Hepar in  De l ivered  Loca l ly  or  
Bonded to Stents  
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• Incomplete Expansion of Coronary Stem: Risk of 
Thromhogenesls end Protection Provided by a 
Hepadn Coating 
John F. Kocsis, Anthony C. Lunn, Syed F. Mohammed 1. Johnson & Johnson 
Interventlonal Systems, Warren, NJ; ~ University of Utah, Salt Lake City, UT 
Palmaz-Sohatz stents, uncoated or with a Carmeda Bioa~tive Surface (CBAS), 
were used to assess the effect of incomplete xpansion and to determine if 
the hapadn coating provided superior thromberesistance in poorly deployed 
slants. Stente were expanded in 3.0 mm polyurethane tubing and subjected 
to 0, 25, or 5~= stenasts using a mechanioal crimping device. Two types of 
restdotions were created: 1) tubing-stent apposition and consffiction, a~d 2) 
constd=lon of the etent with a gap between the tubing and the slant. Constric- 
tions were located either at the midsection of the proximal slant segment, or 
at the proximal end of the stent. The stem-containing tubing was inserted into 
an in vitro test model consisting of a pneumatically.driven ventricle, tdleaflot 
valves and • blood reservoir. Fresh hepadnized bovine blood with autolog0us 
111 ledium-labgled platetats was cimutated at an initial blood flow rate of 100 
4- 20 mVmin through each test conduit, and blood flow was monitored con- 
tinuously. Platalet deposition was quantitated by gamma counting. Results: 
1) Unrestricted stente: the heparin coating reduced platelet deposition by 
91% (p < 0.05); 2) Sfente with 25% restriction: the heparin coating reduced 
plateiot deposition by 68% (p = 0.05); 3) Stente with 50% restriction:the hep- 
arin coating reduced ptatelet deposition by 50% (not s tab ly  significant). 
The CBAS hepadn coating provided protection against platelet deposition in 
fully expanded as well as in incompletely expanded stents, suggesting that 
the hepadn coating may offer added protection in the event that slants are 
not fully expanded when deployed. 
Heparln Coating Dramatically Reduces Platelet 
Deposit ion on ~cempletely Deployed 
Polmaz-Schatz in th~ Baboon A-V Shunt 
Nicolas A.F. Chmnos 2, Keith A. Robinson ;, Deborah White2 Spencer 
B. King III 1, John Koscis 3, Anthony Lunn 3 Andrew Kelly ~, 
Lawrence Harker 2. 3 Johnson and Johnson Intetvenfional Systems/no, 
Warren, NJ; ~ Andreas Gruentzig Cardiovascular Center, Atlanta, GA; 
2 Divis~'on of Hematology of Emery University, Atlanta, GA 
intrsvescular Ultrasound studies have established the s.tgnifioant frequency 
of inadequately deployed intraoorenary stents. To investigate the efficacy of 
a covaiontly bound hepadn [Carmeda ® Bioactive Surface (CBAS)] in reduc- 
ing stent thrombosis despite incomplete deployment, we used the baboon 
exteriorized A-V-shunt model Palmaz-Schatz" PS153 stents were deployed 
in 3.2 mm (i.d.) silicone tubing by 7 elm balloon inflations. A mechanical 
crimping device produced reproducible patterns of stent constriction (25=/0 
and 50% by diameter). Four types of constriction were created: (WA) waft 
apposition to the stem in which the silicone tubing was maintained by a wire 
placed around the silicone tube: (SWG) in which a gap was created between 
the slant and the silicone tube; restrictions were at the proximal end (PER) or 
within the proximal segment (POCR) of the uni*articulated stent. The slanted 
tubing segme=ts were introduced into the non.anticoagulated exte;torized 
A-V shunt and bleed flow was maintained at t 00 ml/min for 2 hours. Platelets 
were prelaboted with m In and fibdnogan with 1251, 
Results: Uncoated slants rapidly recruited platelats and by 90 minutes all 
stanosed slants had occluded. With the heparin coating there was no piotelet 
deposition detestable throughout the tuff 120 minutes of the shunt studies (p 
< 0.0001). Only occasional adherent platelets and microthmmbi were seen 
by scanning etectmn microscopy. 
Uncoated 30 rain 60 rain go rain 
25% SWG, PEfl 0.~-~ .:E 0.08 2.08 ~0~°9 2.34 :b 0.23 
25%WA, POCR 1.70d: 0.63 2.95:E 0.09 occluded 
50% SWG, PER 0.77 d: 0.00 1.59 :E 0.00 occluded 
50% WA, POCR 0.49 ~ 0*00 1.66:1:0*00 OCCluded 
Coaled 30 rain 80 min 90 rain 
25% SWG, PER 0.03 d:0,0t 0.03 4-0.01 0.03±0.01 
25% WA, POCR 0.02 • 0.0 ~, 0*07:1:0.03 0.10 =f= 0.05 
50% SWG, PER 0.00 ±0.00 0.07 :b0.00 0.t6 =t: 0.00 
50% WA, POCR 0.00 *" 0*00 0.02 ± 0.00 0.06 • 0.00 
Discussion: CBAS hepadn coating of the slant eliminated occlusive throm- 
bosis and markedly reduced platalet adhesion in incompletely deployed 
slants. Thus because the heparin coating currently utilized in the Becestent 
I1 study is thrembo-reslstant there is little risk of acute thrombotic closure 
associated with incomplete stem deployment. 
Heparln Coated Polmaz-Schalz" Stents Are Highly 
• Thrombo-Reslstanl: A Baboon A.V Shunt Study 
Nicolas A.R Chrenos 2, Keith A, Robinson 1 Spencer S. King III I, 
Anthony Lunn 3, Deborah White 2, Andrew B. Kelly 2, Laurence A. Herker 2. 
a Johnson and Johnson Intetvantional Systems, Warren, NJ; ~ Andreas 
Gruentzig Cardiovascular Center, Atlanta, GA; 2 Division of Hematology of 
Emery University, Atlanta, GA 
Palmaz-Schatz TM 1 PS153 stents bearing covalently bound hepadn [Carmeda ® 
Bioaciive Surface (CBAS)] are currently being tested in clinical studies in Eu- 
ropa (BENESTENT II). Preliminary animal studies revealed good entithrem- 
botts properties. To further charectedse the hepadn coating and assess the 
maximum: ttithrembotio Potential in reducing stent thrembosLs, we have per- 
formed studies in the baboon exteriorized A,V-shunt model of thrombosis. 
Palmaz-Schatz TM PS153 slants were deployed in 3.2 mm (i.d.) silicone tubing 
using a balloon catheter inflated to 7 atmospheres. The stented tubing seg- 
ments were introduced into the non-anticoagulated exteriorized A-V primate 
shunt and blood flow was maintained at 100 ml/mln for 2 hours. Plalelete 
were pretabaled with 1~1 h~ and flbrinngen with 12Sl. 
